Neal J Weinreb

List of Publications by Year
in descending order

84 papers	4,090 citations	186209 28 h-index	114418 63 g-index
104 all docs	104 docs citations	104 times ranked	2501 citing authors

#	Article	IF	Citations
1	Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. American Journal of Medicine, 2002, 113, 112-119.	0.6	491
2	The Gaucher Registry. Archives of Internal Medicine, 2000, 160, 2835.	4.3	451
3	Therapeutic goals in the treatment of Gaucher disease. Seminars in Hematology, 2004, 41, 4-14.	1.8	418
4	Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. Journal of Medical Genetics, 2015, 52, 353-358.	1.5	266
5	Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood, 2005, 105, 4569-4572.	0.6	221
6	Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. Seminars in Hematology, 2004, 41, 15-22.	1.8	215
7	Gaucher Disease: A Comprehensive Review. Critical Reviews in Oncogenesis, 2013, 18, 163-175.	0.2	125
8	The incidence of Parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry. Blood Cells, Molecules, and Diseases, 2011, 46, 95-102.	0.6	124
9	Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology, 2017, 22, 65-73.	0.7	123
10	Gaucher disease: Progress and ongoing challenges. Molecular Genetics and Metabolism, 2017, 120, 8-21.	0.5	112
11	Longâ€term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. Journal of Inherited Metabolic Disease, 2013, 36, 543-553.	1.7	104
12	Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. British Journal of Haematology, 2009, 147, 561-570.	1.2	97
13	Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells, Molecules, and Diseases, 2011, 46, 66-72.	0.6	95
14	Gaucher Disease in Bone: From Pathophysiology to Practice. Journal of Bone and Mineral Research, 2019, 34, 996-1013.	3.1	94
15	Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. Journal of Pediatrics, 1996, 129, 149-153.	0.9	90
16	A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. American Journal of Hematology, 2008, 83, 890-895.	2.0	77
17	Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: A study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Journal of Bone and Mineral Research, 2012, 27, 1839-1848.	3.1	77
18	Life expectancy in Gaucher disease type 1. American Journal of Hematology, 2008, 83, 896-900.	2.0	72

#	Article	IF	Citations
19	A validated disease severity scoring system for adults with type 1 Gaucher disease. Genetics in Medicine, 2010, 12, 44-51.	1.1	66
20	Enzyme replacement and substrate reduction therapy for Gaucher disease. The Cochrane Library, 2015, 2015, CD010324.	1.5	62
21	Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Molecular Genetics and Metabolism, 2016, 117, 95-103.	0.5	57
22	Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opinion on Pharmacotherapy, 2008, 9, 1987-2000.	0.9	43
23	Presenting signs and patient coâ€variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GEDâ€C) Delphi initiative. Internal Medicine Journal, 2019, 49, 578-591.	0.5	39
24	Hepatocellular carcinoma in Gaucher disease: an international case series. Journal of Inherited Metabolic Disease, 2018, 41, 819-827.	1.7	37
25	Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. American Journal of Hematology, 2017, 92, 929-939.	2.0	35
26	Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4â€“5Âyears. British Journal of Haematology, 2012, 158, 528-538.	1.2	33
27	Causes of Death Due to Hematological and Non-Hematological Cancers in 57 US Patients with Type 1 Gaucher Disease Who Were Never Treated with Enzyme Replacement Therapy. Critical Reviews in Oncogenesis, 2013, 18, 177-195.	0.2	29
28	Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3). Orphanet Journal of Rare Diseases, 2015, 10, 64.	1.2	28
29	Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Molecular Genetics and Metabolism, 2021, 132, 100-111.	0.5	28
30	Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy. Blood Cells, Molecules, and Diseases, 2018, 68, 211-217.	0.6	27
31	A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. Genetics in Medicine, 2014, 16, 359-366.	1.1	25
32	Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. Molecular Genetics and Metabolism, 2020, 130, 164-169.	0.5	25
33	Reducing selection bias in case-control studies from rare disease registries. Orphanet Journal of Rare Diseases, 2011, 6, 61.	1.2	24
34	Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease. JIMD Reports, 2015, 25, 95-106.	0.7	22
35	The history and accomplishments of the ICGG <scp>G</scp>aucher registry. American Journal of Hematology, 2015, 90, S2-5.	2.0	19
36	Prevalence of Type 1 Gaucher Disease in the United States. Archives of Internal Medicine, 2008, 168, 326.	4.3	18

#	Article	IF	Citations
37	The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?. Molecular Genetics and Metabolism, 2022, 136, 4-21.	0.5	18
38	MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association. Blood, 2018, 131, 2500-2501.	0.6	16
39	Multiple myeloma and Gaucher genes. Genetics in Medicine, 2009, 11, 134-134.	1.1	15
40	Gaucher disease: Resetting the clinical and scientific agenda. American Journal of Hematology, 2009, 84, 205-207.	2.0	15
41	Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes. Orphanet Journal of Rare Diseases, 2014, 9, 45.	1.2	15
42	The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 205-218.	2.2	15
43	Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment NaÃ¯ve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa. JIMD Reports, 2015, 23, 7-15.	0.7	13
44	GBA1 mutations: Prospects for exosomal biomarkers in Î±-synuclein pathologies. Molecular Genetics and Metabolism, 2020, 129, 35-46.	0.5	11
45	Splenomegaly, hypersplenism, and hereditary disorders with splenomegaly. Open Journal of Genetics, 2013, 03, 24-43.	0.1	11
46	Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials. Orphanet Journal of Rare Diseases, 2022, 17, 9.	1.2	10
47	Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Molecular Genetics and Metabolism, 2022, 135, 154-162.	0.5	10
48	Patients with Gaucher disease display systemic oxidative stress dependent on therapy status. Molecular Genetics and Metabolism Reports, 2020, 25, 100667.	0.4	9
49	JAK2V617F mutation and myeloproliferative malignancy in a patient with Type 1 Gaucher disease. Blood Cells, Molecules, and Diseases, 2011, 46, 103-104.	0.6	8
50	Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014. American Journal of Hematology, 2014, 89, 457-458.	2.0	6
51	A new framework for evaluating the health impacts of treatment for Gaucher disease type 1. Orphanet Journal of Rare Diseases, 2017, 12, 38.	1.2	5
52	The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients. Orphanet Journal of Rare Diseases, 2021, 16, 92.	1.2	5
53	Early access experience with VPRIVÂ®: Recommendations for â€˜core dataâ€™ collection. Blood Cells, Molecules, and Diseases, 2011, 47, 140-142.	0.6	4
54	Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy. Journal of Inherited Metabolic Disease, 2020, 43, 564-573.	1.7	4

#	Article	IF	Citations
55	Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS). Orphanet Journal of Rare Diseases, 2022, 17, 145.	1.2	4
56	Roscoe Owen Brady, MD: Remembrances of co-investigators and colleagues. Molecular Genetics and Metabolism, 2017, 120, 1-7.	0.5	3
57	A Report from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Blood, 2008, 112, 3549-3549.	0.6	3
58	Avascular Necrosis in Untreated Patients with Type 1 Gaucher Disease.. Blood, 2009, 114, 1353-1353.	0.6	3
59	Mesenchymal gaucho homing on the range. Blood, 2009, 114, 3134-3135.	0.6	2
60	Bone disease in patients with Gaucher disease. Expert Review of Endocrinology and Metabolism, 2014, 9, 153-162.	1.2	2
61	Encore! Oral therapy for type 1 Gaucher disease. Blood, 2017, 129, 2337-2338.	0.6	2
62	Preliminary N-acetylcysteine results for LDN 6722 - Role of oxidative stress and inflammation in Gaucher disease type 1: Potential use of antioxidant anti-inflammatory medications. Molecular Genetics and Metabolism, 2019, 126, S82.	0.5	2
63	Preface: Gaucher Disease and Cancer. Critical Reviews in Oncogenesis, 2013, 18, .	0.2	1
64	Patient Management Problem. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 402-406.	0.4	0
65	Patient Management Problem-Preferred Responses. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 407-416.	0.4	0
66	A 10-year study documenting the long-term effectiveness of agalsidase-beta treatment in 52 adult patients with classic Fabry disease. Molecular Genetics and Metabolism, 2015, 114, S45-S46.	0.5	0
67	Imiglucerase treatment associated with reduction of bone claims in Gaucher's patients: Analysis of US claims data. Molecular Genetics and Metabolism, 2015, 114, S85.	0.5	0
68	Maintenance of quality of life in adults with type 1 Gaucher disease previously stabilized on enzyme therapy who were switched to oral eliglustat: 4 year results of the ENCORE trial. Molecular Genetics and Metabolism, 2017, 120, S37-S38.	0.5	0
69	Transformation in pre-treatment presentations of Gaucher disease during the first two decades of imiglucerase enzyme replacement therapy: a report from the International Collaborative Gaucher Group Gaucher Registry. Molecular Genetics and Metabolism, 2017, 120, S139.	0.5	0
70	Gaucher disease and associated plasma cell neoplasia: A diagnostic dilemma. Molecular Genetics and Metabolism, 2019, 126, S128-S129.	0.5	0
71	Baseline characteristics of patients with Gaucher disease enrolled in the taliglucerase alfa surveillance (TALIAS) registry. Molecular Genetics and Metabolism, 2019, 126, S143.	0.5	0
72	A composite fracture risk score for assessing adult fracture risk in imiglucerase-treated type 1 Gaucher disease patients using data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Molecular Genetics and Metabolism, 2019, 126, S47.	0.5	0

#	Article	IF	Citations
73	Gaucher disease type 1 severity and risk for liver fibrosis in untreated patients and in patients treated primarily with enzyme replacement therapy for a median of 20 years. Molecular Genetics and Metabolism, 2019, 126, S151.	0.5	0
74	Long-Term Data From the ICGG Gaucher Registry: Clinical Parameters After 10 Years of Treatment with Imiglucerase.. Blood, 2009, 114, 3590-3590.	0.6	0
75	Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4â€“5 Years. Blood, 2010, 116, 4719-4719.	0.6	0
76	Thrombocytopenia in the Absence of Splenomegaly in Patients with Type 1 Gaucher Disease: A Preliminary Analysis From the ICGG Gaucher Registry,. Blood, 2011, 118, 4217-4217.	0.6	0
77	Report on the Safety of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease and the Transition From Clinic to Home Infusions During Treatment Protocol HGT-GCB-058. Blood, 2011, 118, 1101-1101.	0.6	0
78	Causes of Death in 184 Patients with Type 1 Gaucher Disease From the United States Who Were Never Treated with Enzyme Replacement Therapy. Blood, 2011, 118, 3128-3128.	0.6	0
79	Evaluation of Disease Burden and Response to Treatment in Adults with Type 1 Gaucher Disase Using a Validated DS3 Severity Score Index. Blood, 2014, 124, 4957-4957.	0.6	0
80	â€œImiglucerase Treatment Associated with Reduction of Bone Claims in Gaucher Patients: Analysis of US Claims Dataâ€• Blood, 2014, 124, 4837-4837.	0.6	0
81	Long-Term Hematologic Response to Eliglustat in Patients with Gaucher Disease Type 1: Results from a Phase 2 and Two Phase 3 Trials. Blood, 2015, 126, 884-884.	0.6	0
82	Transformation in Pre-Treatment Presentations of Gaucher Disease during the First Two Decades of Imiglucerase Enzyme Replacement Therapy: A Report from the International Collaborative Gaucher Group Gaucher Registry. Blood, 2016, 128, 4877-4877.	0.6	0
83	Type 1 Gaucher Disease Severity and Risk for Liver Fibrosis in Untreated Patients and in Patients Treated Primarily with Enzyme Replacement Therapy for a Median of 20 Years. Blood, 2018, 132, 2403-2403.	0.6	0
84	Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials. Blood, 2019, 134, 4859-4859.	0.6	0